ABCB1 and breast carcinoma: Additionally, dasatinib was able to alter ABCB1 expression level by inhibiting the ERK (Extracellular signal-related kinase) pathway activation in Adriamycin-resistant breast cancer cells (MCF-7/ADR)47.